Myriad Genetics Statistics
Total Valuation
Myriad Genetics has a market cap or net worth of $463.65 million. The enterprise value is $529.45 million.
Important Dates
The next estimated earnings date is Tuesday, August 5, 2025, after market close.
| Earnings Date | Aug 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Myriad Genetics has 92.18 million shares outstanding. The number of shares has increased by 7.09% in one year.
| Current Share Class | 92.18M |
| Shares Outstanding | 92.18M |
| Shares Change (YoY) | +7.09% |
| Shares Change (QoQ) | +0.33% |
| Owned by Insiders (%) | 2.56% |
| Owned by Institutions (%) | 101.93% |
| Float | 89.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 123.89 |
| PS Ratio | 0.55 |
| Forward PS | 0.55 |
| PB Ratio | 0.66 |
| P/TBV Ratio | 2.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.90, with a Debt / Equity ratio of 0.22.
| Current Ratio | 1.90 |
| Quick Ratio | 1.40 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -28.74 |
Financial Efficiency
Return on equity (ROE) is -13.84% and return on invested capital (ROIC) is -6.29%.
| Return on Equity (ROE) | -13.84% |
| Return on Assets (ROA) | -5.26% |
| Return on Invested Capital (ROIC) | -6.29% |
| Return on Capital Employed (ROCE) | -10.42% |
| Revenue Per Employee | $307,889 |
| Profits Per Employee | -$37,556 |
| Employee Count | 2,700 |
| Asset Turnover | 0.79 |
| Inventory Turnover | 9.43 |
Taxes
| Income Tax | -25.60M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -78.65% in the last 52 weeks. The beta is 1.85, so Myriad Genetics's price volatility has been higher than the market average.
| Beta (5Y) | 1.85 |
| 52-Week Price Change | -78.65% |
| 50-Day Moving Average | 5.96 |
| 200-Day Moving Average | 14.36 |
| Relative Strength Index (RSI) | 47.70 |
| Average Volume (20 Days) | 2,201,255 |
Short Selling Information
The latest short interest is 8.78 million, so 9.52% of the outstanding shares have been sold short.
| Short Interest | 8.78M |
| Short Previous Month | 7.92M |
| Short % of Shares Out | 9.52% |
| Short % of Float | 9.78% |
| Short Ratio (days to cover) | 2.62 |
Income Statement
In the last 12 months, Myriad Genetics had revenue of $831.30 million and -$101.40 million in losses. Loss per share was -$1.12.
| Revenue | 831.30M |
| Gross Profit | 582.00M |
| Operating Income | -89.10M |
| Pretax Income | -156.60M |
| Net Income | -101.40M |
| EBITDA | -29.20M |
| EBIT | -89.10M |
| Loss Per Share | -$1.12 |
Full Income StatementBalance Sheet
The company has $91.80 million in cash and $157.60 million in debt, giving a net cash position of -$65.80 million or -$0.71 per share.
| Cash & Cash Equivalents | 91.80M |
| Total Debt | 157.60M |
| Net Cash | -65.80M |
| Net Cash Per Share | -$0.71 |
| Equity (Book Value) | 704.90M |
| Book Value Per Share | 7.65 |
| Working Capital | 136.10M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$6.40 million and capital expenditures -$17.60 million, giving a free cash flow of -$24.00 million.
| Operating Cash Flow | -6.40M |
| Capital Expenditures | -17.60M |
| Free Cash Flow | -24.00M |
| FCF Per Share | -$0.26 |
Full Cash Flow StatementMargins
Gross margin is 70.01%, with operating and profit margins of -10.72% and -12.20%.
| Gross Margin | 70.01% |
| Operating Margin | -10.72% |
| Pretax Margin | -15.28% |
| Profit Margin | -12.20% |
| EBITDA Margin | -3.51% |
| EBIT Margin | -10.72% |
| FCF Margin | n/a |
Dividends & Yields
Myriad Genetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.09% |
| Shareholder Yield | -7.09% |
| Earnings Yield | -21.87% |
| FCF Yield | -5.18% |
Dividend DetailsAnalyst Forecast
The average price target for Myriad Genetics is $15.14, which is 200.99% higher than the current price. The consensus rating is "Hold".
| Price Target | $15.14 |
| Price Target Difference | 200.99% |
| Analyst Consensus | Hold |
| Analyst Count | 15 |
| Revenue Growth Forecast (5Y) | 5.20% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 26, 2009. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 26, 2009 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Myriad Genetics has an Altman Z-Score of 3.26 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.26 |
| Piotroski F-Score | 3 |